

External validation of the fatty liver index and lipid accumulation product indices, using ^1H -magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals

Daniel J Cuthbertson^{1,2}, Martin O Weickert^{3,4}, Daniel Lythgoe⁵, Victoria S Sprung^{1,2}, Rebecca Dobson^{1,2}, Fariba Shoajee-Moradie⁶, Margot Umpleby⁶, Andreas F H Pfeiffer^{7,8}, E Louise Thomas⁹, Jimmy D Bell⁹, Helen Jones¹⁰ and Graham J Kemp¹¹

¹Department of Obesity and Endocrinology, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK,

²Department of Obesity and Endocrinology, Institute of Ageing and Chronic Disease, University of Liverpool,

Liverpool, UK, ³Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University

Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, ⁴Division of Metabolic and Vascular Health,

Warwick Medical School, University of Warwick, Warwick, UK, ⁵Cancer Research UK Liverpool Cancer Trials Unit,

University of Liverpool, Liverpool, UK, ⁶Department of Diabetes and Metabolic Medicine, Faculty of Health and

Medical Sciences, University of Surrey, Guildford, UK, ⁷Department of Clinical Nutrition, German Institute of Human

Nutrition, Potsdam-Rehbruecke, Germany, ⁸The Department of Endocrinology, Diabetes and Nutrition,

Charité-University-Medicine Berlin, Berlin, Germany, ⁹Metabolic and Molecular Imaging Group,

Imperial College London, MRC Clinical Sciences Centre, London, UK, ¹⁰Research Institute for Sport and

Exercise Sciences, Liverpool John Moores University, Liverpool, UK and ¹¹Department of Musculoskeletal Biology,

Institute of Ageing and Chronic Disease, Magnetic Resonance and Image Analysis Research Centre,

University of Liverpool, Liverpool, UK

Correspondence
should be addressed
to D J Cuthbertson
Email
daniel.cuthbertson@
liverpool.ac.uk

Abstract

Background and aims: Simple clinical algorithms including the fatty liver index (FLI) and lipid accumulation product (LAP) have been developed as surrogate markers for non-alcoholic fatty liver disease (NAFLD), constructed using (semi-quantitative) ultrasonography. This study aimed to validate FLI and LAP as measures of hepatic steatosis, as determined quantitatively by proton magnetic resonance spectroscopy ($^1\text{H-MRS}$).

Methods: Data were collected from 168 patients with NAFLD and 168 controls who had undergone clinical, biochemical and anthropometric assessment. Values of FLI and LAP were determined and assessed both as predictors of the presence of hepatic steatosis (liver fat $>5.5\%$) and of actual liver fat content, as measured by $^1\text{H-MRS}$. The discriminative ability of FLI and LAP was estimated using the area under the receiver operator characteristic curve (AUROC). As FLI can also be interpreted as a predictive probability of hepatic steatosis, we assessed how well calibrated it was in our cohort. Linear regression with prediction intervals was used to assess the ability of FLI and LAP to predict liver fat content. Further validation was provided in 54 patients with type 2 diabetes mellitus.

Results: FLI, LAP and alanine transferase discriminated between patients with and without steatosis with an AUROC of 0.79 (IQR = 0.74, 0.84), 0.78 (IQR = 0.72, 0.83) and 0.83 (IQR = 0.79, 0.88) respectively although could not quantitatively predict liver fat. Additionally, the algorithms accurately matched the observed percentages of patients with hepatic steatosis in our cohort.

Conclusions: FLI and LAP may be used to identify patients with hepatic steatosis clinically or for research purposes but could not predict liver fat content.

*European Journal of
Endocrinology*
(2014) 171, 561–569

Introduction

Non-alcoholic fatty liver disease (NAFLD) is increasingly recognised as a major public health concern, being highly prevalent in the general population, particularly in individuals with features of the metabolic syndrome (1). NAFLD encompasses a disease spectrum, ranging from simple steatosis, through to an inflammatory state (non-alcoholic steatohepatitis, NASH) and culminating in fibrosis and liver cirrhosis (2). In addition to the known association with liver-related morbidity and mortality, NAFLD patients have an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (3, 4).

Liver transaminases and abdominal ultrasonography are insensitive in detecting NAFLD, with liver function tests normal in up to 79% of patients and ultrasonography requiring a moderately high liver fat for NAFLD to be recognised (5). Only histological examination or proton magnetic resonance spectroscopy ($^1\text{H-MRS}$) can quantitatively assess liver fat (more exactly, hepatocellular lipid content) (3, 4).

Non-invasive algorithms based on metabolic and anthropometric variables, such as the fatty liver index (FLI), lipid accumulation product (LAP), the hepatic steatosis index (HIS) and the Finnish Diabetes Risk Score (FINDRISC) (6, 7, 8, 9, 10, 11), have been used as a screening test for hepatic steatosis and identify potential patients for further clinical investigation or for epidemiologic studies. They have been applied in various clinical populations to assess prevalence of NAFLD (12) and to provide prognostic information about incident risk of metabolic syndrome and type 2 diabetes, cardiovascular disease and risk of mortality in various sub-groups (13, 14, 15, 16, 17, 18).

The original studies to propose FLI and LAP were validated using ultrasonography (2, 7, 19), as well as the SteatoTest, an alternative biochemical surrogate marker of liver steatosis (20). Liver biopsy is an invasive method. The only study to validate FLI using $^1\text{H-MRS}$, which is supposed to be the next best method as compared with liver biopsy, involved only 25 subjects, with the results

suggesting a nonlinear relationship between FLI and hepatocellular lipid content (21).

This study aimed to evaluate the ability of FLI and the LAP to discriminate between patients with and without hepatic steatosis, based on simple clinical and biochemical variables; and to evaluate their ability to predict liver fat content based on our non-invasive measurement of liver fat by $^1\text{H-MRS}$. Here, we combined data from several large cohorts of participants with detailed characterisation of clinical, metabolic and anthropometric parameters, in whom $^1\text{H-MRS}$ measurement of liver fat had been performed for several different research projects.

Methods

Study participants

We analysed data from participants recruited into human metabolic studies from four research centres (University of Liverpool, University of Surrey, Charite University Berlin and German Institute of Human Nutrition, Potsdam-Rehbruecke) from primary and secondary care. We recruited healthy controls and individuals with components of the metabolic syndrome including being overweight/obese ($\text{BMI} > 25 \text{ kg/m}^2$), with a waist circumference $> 80 \text{ cm}$ in females and $> 94 \text{ cm}$ in males, and with at least one additional feature of the metabolic syndrome according to International Diabetes Federation criteria (22). Clinical characteristics of the cohorts have been presented previously in detail (23, 24). All participants gave written informed consent, and ethical approval was obtained from the respective local ethics committee.

Exclusion criteria

We excluded participants with a history of type 1 diabetes mellitus, pregnancy, any significant history of endocrine, cardiovascular, renal or hepatic disease and standard MR contraindications. Other causes of chronic liver disease

were excluded by taking a careful alcohol and drug history and performing an autoimmune liver screen and hepatitis serology. We excluded males with alcohol intake >21 units per week and females with >14 units per week and any individuals with a history of alcohol excess.

Anthropometric assessments

Trained physicians performed all anthropometry measurements. BMI was calculated in kg/m²; waist circumference was measured midway between the lower rib margin and the iliac crest.

Biochemical assessment

All participants underwent a biochemical assessment, and fasting triglycerides, alanine transferase (ALT) and gamma-glutamyl transferase (GGT) were measured. Routine laboratory markers were measured from venous blood samples using standard methods in the research laboratories of respective centres (University Hospital Aintree, Liverpool, Royal Surrey County Hospital and in the German Institute of Human Nutrition).

Proton magnetic resonance spectroscopy

All ¹H-MRS measurements of liver fat were performed in the fasting state. Lipid content in the liver was measured by localised ¹H-MRS, using an Intera 1.5T Achieva (Philips Medical Systems, Best, The Netherlands) for the Surrey participants (25), a Magnetom 1.5T Symphony MR (Siemens Healthcare, Erlangen, Germany) for the Liverpool participants (26), and a Magnetom 1.5T Avanto (Siemens Healthcare) for the German participants. Single voxel spectroscopy was used: for the German studies, STEAM with VOI 30×30×30 mm, 32 acquisitions, TR=4000 ms, TM=15 ms, TE=10 ms; for the UK studies, PRESS with VOI 20×20×20 mm (three voxels, results averaged), 64 acquisitions, TR=1500 ms, TE 135 ms (25). Spectra were quantified using the AMARES algorithm included in the jMRUI software package, incorporating standard prior knowledge. For the German studies, signal integrals of water (H₂O at 4.8 ppm) and lipids (CH₂ and CH₃ at 1.25 and 0.95 ppm) were quantified manually in fixed frequency intervals (water: 3.1–6.2 ppm, lipids: 0.5–1.8 ppm); for the UK studies, these signal amplitudes were obtained directly from the AMARES fit. Liver fat is expressed as percentage of CH₂ lipid signal amplitude relative to water signal amplitude after correcting for T₁ and T₂ (25). Liver fat content (%) was quantified but also coded ordinally as none (≤5.5%) or present (>5.5%).

Calculations

FLI was calculated using BMI (kg/m²), serum triglyceride (mg/dl) and GGT (U/l) concentrations and waist circumference (cm) according to Bedogni *et al.* (7) to obtain a score between 0 and 100:

$$FLI = \frac{\exp(\eta)}{1 + \exp(\eta)} \times 100,$$

where,

$$\eta = 0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \\ \times \ln(\text{ggt}) + 0.053 \times \text{waist circumference} - 15.754.$$

LAP was calculated using serum triglycerides (mmol/l) and waist circumference (cm) using sex-specific calculations (9):

$$LAP_{\text{men}} = (\text{waist circumference} - 65) \times \text{triglycerides} \\ LAP_{\text{women}} = (\text{waist circumference} - 58) \times \text{triglycerides}.$$

Statistical analysis

Baseline demographic variables are reported as means and s.d. or median and interquartile range depending on their distribution. Distributional assumptions were assessed using Q-Q plots. Categorical variables are reported as frequencies and percentages. Statistical comparisons of patients with and without hepatic steatosis were undertaken for all demographic variables; χ^2 tests were used for categorical variables and unpaired *t*-tests or Mann-Whitney *U* tests for continuous variables, depending on whether relevant distributional assumptions were met.

To assess the ability of a variable to discriminate between patients with and without hepatic steatosis, receiver operator characteristic (ROC) curves were constructed for FLI, LAP, BMI, waist circumference and ALT. In addition, for FLI and LAP, we measured a number of other diagnostic statistics: the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio at various cut-points.

As FLI can also be interpreted as a predictive probability for hepatic steatosis, we assessed how well-calibrated FLI was in our patient cohort using a calibration plot (27). To do so, we grouped patients into deciles based on measured FLI and within each decile calculated the proportion of patients with hepatic steatosis. If a variable is well calibrated, the observed percentages should be close to the 'line of equality', which represents perfect calibration: roughly 50% of patients should have hepatic steatosis at an FLI of around 50 etc.

Linear regression with 95% prediction intervals (PI) was used to determine whether liver fat content could be predicted using FLI or LAP alone. PIs are to be interpreted as the range of values for liver fat we would assign to a new patient with a given FLI/LAP with 95% 'confidence'. Linear regression assumptions were assessed using plots of residuals vs fitted values and Q-Q plots of the residuals. It was necessary to logarithmically transform both liver fat and LAP for these purposes; the linear regression line and PI, while linear on the log scale, are nonlinear, non-constant and asymmetric on the original scale. For simplicity, we evaluated their predictive performance at the mean FLI/LAP.

Results

Characteristics of the participants without T2DM

Table 1 reports the clinical, biochemical and anthropometric characteristics of the participants (178 males (53%)

Table 1 Baseline clinical, anthropometric and biochemical characteristics of participants. Categorical variables compared using χ^2 test. Continuous variables compared using the unpaired *t*-tests or Mann-Whitney *U* tests depending on whether data met the relevant distributional assumptions.

	Controls	Hepatic steatosis	P
<i>n</i>	168 (50%)	168 (50%)	–
Male	61 (34%)	116 (66%)	<0.0005
Female	107 (67%)	52 (33%)	
Liver fat (%)	1.8 (1.0, 3.1)	16.6 (9.1, 30.7)	0.0001
Age (years)	48.6 (11.9)	50.3 (10.9)	0.19
Weight (kg)	83.3 (72.5, 93.2)	93.4 (84.6, 104.6)	0.29
BMI (kg/m ²)	29.2 (26.7, 32.3)	31.2 (28.9, 33.9)	0.0001
Waist (cm)	98.4 (89.9, 104.8)	105.8 (100.5, 113.0)	0.0001
Fasting glucose (mmol/l)	4.80 (4.50, 5.10)	5.00 (4.70, 5.40)	0.0001
Cholesterol (mmol/l)	5.00 (4.55, 5.80)	5.50 (4.87, 6.02)	0.0135
Triglycerides (mmol/l)	1.01 (0.80, 1.30)	1.60 (1.11, 2.32)	0.0001
HDL (mmol/l)	1.40 (1.20, 1.68)	1.20 (1.05, 1.42)	0.0001
LDL (mmol/l)	3.12 (2.64, 3.80)	3.30 (2.80, 3.92)	0.14
Chol:HDL ratio	3.67 (3.00, 4.24)	4.29 (3.81, 5.26)	0.0001
AST (U/l)	21 (18, 24)	28 (23, 35)	0.0001
ALT (U/l)	19 (16, 26)	37 (26, 56)	0.0001
GGT (U/l)	20 (13, 29)	37 (21, 58)	0.0001
FLI	18.8 (8.0, 37.6)	56.2 (31.3, 72.8)	0.0001
LAP	40.0 (25.1, 53.6)	72.8 (47.5, 99.2)	0.0001

Categorical variables reported as frequency (%) and continuous variables as mean (s.d.) or median (IQR).

and 158 females). Participants were sub-divided into two groups, healthy controls or hepatic steatosis, according to their liver fat measured by ¹H-MRS (liver fat <5.5%, healthy controls; >5.5% NAFLD). Using this threshold, 50% of participants (*n*=168) had hepatic steatosis (116 males (66%)) and 50% (*n*=168) were healthy controls (61 males (34%)). The two groups were mean-matched for age.

Participants with hepatic steatosis were more obese, with significantly greater weight, BMI and waist circumference, than the healthy controls. Those with hepatic steatosis demonstrated multiple components of the metabolic syndrome with significantly greater serum fasting glucose (4.8 mmol/l (IQR=4.5, 5.1) vs 5.0 mmol/l (IQR=4.7, 5.4)), triglycerides (1.0 mmol/l (IQR=0.8, 1.3) vs 1.6 mmol/l (IQR=1.1, 2.3)) and lower HDL concentrations (1.4 mmol/l (IQR=1.2, 1.7) vs 1.2 mmol/l (IQR=1.1, 1.4)) than the healthy control group (Table 1).

The median liver fat significantly differed in the healthy control group 1.84% (IQR=1.00, 3.13) as compared with the hepatic steatosis group 16.58% (IQR=9.10, 30.70). The distribution of liver fat within the hepatic steatosis group is shown in Fig. 1. Measurements of liver fat were reflected in the liver biochemistry with significantly greater liver transaminases (AST and ALT) and serum GGT in the hepatic steatosis group. Patients with hepatic steatosis had significantly higher FLI (56.21 (IQR=31.43, 72.75) vs 18.77 (IQR=8.00, 37.60)) and LAP (72.75 (IQR=47.53, 99.24) vs 39.96 (IQR=25.11, 53.64)) than participants in the control group.

ROC curves

ROC curves were constructed and area under the ROC curve (AUROC) with NAFLD defined as liver fat >5.5% on MRS (Fig. 2). Both LAP and FLI were able to discriminate between patients with and without hepatic steatosis. The AUROC for LAP was 0.78 (IQR=0.72, 0.83) and for FLI was 0.79 (IQR=0.74, 0.84). There was no evidence that AUROC for LAP and FLI differed (*P*=0.49). There was no significant difference in AUROC for either FLI or LAP between males and females (Table 2).

We also considered the AUROC for BMI, waist circumference, ALT, triglycerides and GGT, which were 0.64 (IQR=0.58, 0.70), 0.73 (IQR=0.67, 0.79), 0.83 (IQR=0.79, 0.88), 0.74 (IQR=0.69, 0.79) and 0.73 (IQR=0.67, 0.78), respectively. We conducted exploratory pairwise comparisons between all seven of these variables and found evidence that both FLI and LAP were superior to waist circumferences and BMI. FLI was also superior to GGT (*P*=0.03) but not to triglycerides (*P*=0.10).




Figure 1
Distribution of liver fat in those with hepatic steatosis.

The reverse was true for LAP, which was superior to triglycerides ($P=0.01$) but not GGT ($P=0.12$). Interestingly, ALT had a similar AUROC to both FLI and LAP.

Sensitivity, specificity, positive likelihood ratios and negative likelihood ratio of FLI and LAP

Table 3 gives the sensitivity, specificity, positive likelihood ratios and negative likelihood ratios for a range of ten-unit intervals for FLI. The intervals chosen were those used by Bedogni *et al.* (7). A cut-off of FLI ≥ 10 gives a sensitivity of 95% and a LR⁻ of 0.15, i.e. an individual without hepatic steatosis is around seven times more likely to have an FLI <10. A cut-off of FLI ≥ 60 gives a specificity of 91% and a LR⁺ of 5.10, i.e. an individual with hepatic steatosis is around five times more likely to have an FLI ≥ 60 . Using these cut-offs, 42% of patients would have avoided the need for a more definitive test (with 77% being classified correctly); 58% would have had an indeterminate classification (an FLI value within the cut-offs).

Table 3 gives the sensitivity, specificity, positive likelihood ratios and negative likelihood ratios for a range of ten-unit intervals for LAP. A cut-off of LAP ≥ 20 gives a sensitivity of 99% and LR⁻ of 0.08, i.e. an individual without hepatic steatosis is around ten times more likely to have a LAP <20. A cut-off of LAP ≥ 80 has a specificity of 94% and LR⁺ of 4.93, i.e. an individual with hepatic steatosis is around five times more likely to have a LAP ≥ 80 . Using these cut-offs, 35% of patients would have avoided the need for a more definitive test (with 86% being classified correctly); 65% would have had an indeterminate classification.

We report these cut-offs in particular because they yield a LR⁺ >5 and a LR⁻ <0.2 and therefore might be used as reasonable 'rule-in' and 'rule-out' criteria respectively.

Calibration of FLI

FLI provides a 'predicted probability' of a patient having hepatic steatosis. The calibration plot in Fig. 3 addresses how satisfactory these predicted probabilities were in our cohort. We have established that FLI discriminates between patients with and without hepatic steatosis (using AUROC analysis), and this is evidenced by the horizontal separation of the two clouds of points, clustered at low FLI values for those without steatosis, and at higher FLI values for those with hepatic steatosis.

We further determined how closely an individual's actual FLI corresponds to their probability of having hepatic steatosis and this relates to calibration. We assessed calibration of FLI by grouping patients according to FLI and calculating the proportion of individuals in each group with hepatic steatosis. The proportion of individuals with hepatic steatosis within each decile is plotted in Fig. 3 (solid circles) with corresponding CIs.

If these proportions closely match the (dashed) line of equality, then FLI is well calibrated and FLI can reliably be used as a predictive probability of hepatic steatosis. The CIs generally include the line of equality and therefore our results indicate that the predicted probabilities of hepatic steatosis given by FLI are consistent with the observed percentages in our cohort, i.e. that FLI is reasonably well calibrated. The point estimates being above the line of equality indicate that FLI may underestimate the probability of a patient having hepatic steatosis and perhaps might be considered a pragmatic lower limit.




Figure 2
Receiver operating characteristics (ROC) analysis of fatty liver index (FLI) to predict the presence or absence of non-alcoholic fatty liver disease (NAFLD).

Table 2 Receiver operating characteristics (ROC) analysis of fatty liver index (FLI) and lipid accumulation product (LAP) to predict the presence or absence of non-alcoholic fatty liver disease (NAFLD) in (A) males and females and (B) original cohort (without T2DM) and with T2DM.

	FLI	LAP
(A)		
Females	0.74 (0.66, 0.82)	0.77 (0.69, 0.85)
Males	0.80 (0.73, 0.87)	0.74 (0.66, 0.82)
<i>P</i> value	0.28	0.59
(B)		
Original	0.79 (0.74, 0.84)	0.78 (0.73, 0.83)
T2DM	0.80 (0.62, 0.97)	0.84 (0.68, 0.99)
<i>P</i> value	0.91	0.50

Predicting hepatocellular lipid content using FLI and LAP

Both FLI and log-transformed LAP were linearly related to log-transformed liver fat (Fig. 4). However, the values of log-transformed liver fat varied considerably about the regression line. This variability is the primary contributor to the width of the 95% PIs and hence determines the estimated predictive ability of each algorithm. If we consider the width of the PIs at FLI=30, a patient's liver fat for this score could plausibly be between around 0 and 40%. For LAP=30, the predicted liver fat could plausibly be between around 0 and 45%. Varying the predictive values of FLI and LAP at other values remained uninformative, suggesting FLI and LAP cannot be used to quantitatively determine liver fat content.

Validation of the models in patients with T2DM

Fifty-four patients with T2DM were recruited to validate the models in patients with T2DM, of whom 45 had hepatic steatosis and nine had normal liver fat. We performed the ROC analysis using only those patients with T2DM then compared it with the initial ROC analysis (Table 2). The non-significant *P* values suggest that the ability of each parameter to correctly classify a subject does not differ for the T2DM patients.

Discussion


Here, we provide external validation for the use of two previously reported indices, the FLI and the LAP, to determine any given individual's probability of having hepatic steatosis, based on simple clinical parameters.

The validation in the current study was performed on a large cohort of individuals with varying degrees of obesity, with and without hepatic steatosis, using ¹H-MRS measurement of liver fat, considered by many to be the gold standard, non-invasive measurement technique.

The predictive models were originally developed using ultrasonography, a semi-quantitative methods capable of defining the degree of steatosis (mild, moderate or severe) (28). ¹H-MRS-derived measures of liver fat can accurately quantify liver fat, validated against liver biopsy specimens (4) with normal liver fat being <5.5% (4). The predictive values of FLI in this study compare favourably with those from Bedogni *et al.* (7) to 'rule out' or 'rule in' hepatic steatosis: an FLI cut point of ten has a 95 vs 98% sensitivity and a negative likelihood ratio 0.15 vs 0.10 respectively, whereas a FLI cut point of 60 has a specificity 91 vs 86% and a positive likelihood ratio of 5.1 vs 4.3 respectively. Thus in our study, an individual without hepatic steatosis was around seven times more likely to have an FLI <10, and an individual with hepatic steatosis was around five times more likely to have an FLI >60. A cut-off of LAP ≥20 had a sensitivity of 99% and LR− of 0.08, i.e. an individual without hepatic steatosis was around ten times more likely to have a LAP <20, while a cut-off of LAP ≥80 has a specificity of 94% and LR+ of 4.93, i.e. an individual with hepatic steatosis is around five times more likely to have a LAP ≥80.

Table 3 FLI and LAP cut-point table; % = proportion of patients with an FLI ≥ cut-point; % = proportion of patients with a LAP ≥ cut-point.

Cut-point	%	SN	SP	LR+	LR−
FLI					
≥ 10	0.83	0.95	0.29	1.35	0.15
≥ 20	0.67	0.86	0.53	1.82	0.27
≥ 30	0.54	0.75	0.69	2.43	0.36
≥ 40	0.45	0.66	0.77	2.84	0.45
≥ 50	0.38	0.56	0.81	3.03	0.54
≥ 60	0.26	0.44	0.91	5.10	0.61
≥ 70	0.18	0.29	0.94	4.87	0.75
≥ 80	0.11	0.19	0.96	4.71	0.85
≥ 90	0.04	0.06	0.99	9.74	0.94
LAP					
≥ 20	0.91	0.99	0.16	1.18	0.08
≥ 30	0.79	0.93	0.34	1.40	0.22
≥ 40	0.68	0.86	0.50	1.71	0.29
≥ 50	0.50	0.70	0.69	2.29	0.43
≥ 60	0.39	0.59	0.81	3.17	0.50
≥ 70	0.34	0.54	0.86	3.74	0.54
≥ 80	0.26	0.43	0.91	4.93	0.62
≥ 90	0.19	0.33	0.94	5.20	0.72
≥ 100	0.14	0.24	0.96	5.43	0.80
≥ 110	0.12	0.2	0.96	5.33	0.83
≥ 120	0.10	0.18	0.97	5.60	0.85

**Figure 3**

The hollow circles represent individual FLI values for each patient: those circles (patients) at the top of the plot have hepatic steatosis and those at the bottom do not (the points have been artificially separated slightly so that overlapping circles are not obscured). Solid circles represent the percentage of patients with hepatic steatosis within each decile of FLI (with corresponding CIs).


The FLI and LAP values are most useful to determine the probability of an individual having hepatic steatosis, but the strength of their relationship with liver fat content is insufficient for accurate prediction. A previous, elegant study by Kotronen *et al.* (29) in a large cohort of Finnish adults, using $^1\text{H-MRS}$ measurements of liver fat, developed a NAFLD liver fat score and an equation distinct from FLI, which has been applied to predict NAFLD and liver fat content. However, in contrast to the indices discussed here, that score required measurement of fasting serum insulin concentrations. Significantly, serum ALT has a similar discriminatory ability to both of these algorithms.

To date, FLI has only been validated in a small group of females ($n=25$) using $^1\text{H-MRS}$ measures of liver fat demonstrating a nonlinear relationship between FLI and liver fat content, limiting its predictive ability (21). Determining the severity of steatosis has arguably only limited clinical utility, mere identification of an individual as having hepatic steatosis, as part of the NAFLD spectrum, being sufficient to trigger prompt assessment and treatment of associated cardio-metabolic complications, and determination of the presence of NASH or fibrosis either non-invasively or by liver biopsy, to reduce the long-term risk of cardiovascular and hepatic complications.

FLI, adopted as a surrogate marker of hepatic steatosis, has been applied in numerous prospective, epidemiological

studies and can predict the risk of incident T2DM (30), the incidence of atherosclerosis and cardiovascular disease (18) and of hepatic-related mortality after 15 years (16). Thus, FLI values have both diagnostic and prognostic significance.

Strengths of this study include the large number of well-characterised individuals with liver fat measured by the gold standard, non-invasive method. Furthermore, the study comprised a cross-section of individuals with normal liver fat and with hepatic steatosis (of a mild, moderate or severe degree). We acknowledge a limitation of the study was that individuals were recruited from three different research sites, thus there was a lack of standardisation of the analytical techniques (i.e. biochemical assays and MRS) between the three centres. However, analysis of the individual data sets from each of the three centres demonstrated similar results. A further limitation, inherent to these algorithms, is that

**Figure 4**

Linear regression with 95% prediction intervals (PI) to determine whether liver fat content (presented as the natural logarithm of liver fat, y axis) can be predicted using FLI (x axis, upper graph) or LAP (x axis, lower graph).

although these values can predict the probability of hepatic steatosis, they have no predictive ability in identifying individuals who may have progressed along the NAFLD spectrum, with NASH or fibrosis.

In summary, we provide an external validation for the use of FLI and LAP using MRS. These results provide reassurance about its legitimacy as a surrogate marker for hepatic steatosis. Their application may be useful clinically, for metabolic research or epidemiological studies.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

Dr D J Cuthbertson and Prof. M Umpleby were supported by the European Foundation for the Study of Diabetes (EFSD).

Author contribution statement

D J Cuthbertson and G J Kemp contributed to the conception and design of the study, drafting and redrafting of the final manuscript. D Lythgoe contributed to the assembly, analysis and interpretation of data. M O Weickert, V S Sprung, R Dobson, F Shoajee-Moradie, M Umpleby, A F H Pfeiffer, E L Thomas, J D Bell and H Jones participated in the generation, collection and assembly of data. V S Sprung, M Umpleby and H Jones also participated in the drafting and redrafting of the manuscript. All authors approved the final version of the manuscript.

References

- Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G & Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005 **42** 44–52. (doi:10.1002/hep.20734)
- Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM & Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004 **40** 1387–1395. (doi:10.1002/hep.20466)
- Cohen JC, Horton JD & Hobbs HH. Human fatty liver disease: old questions and new insights. *Science* 2011 **332** 1519–1523. (doi:10.1126/science.1204265)
- Szczepaniak LS, Nuremberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH & Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *American Journal of Physiology. Endocrinology and Metabolism* 2005 **288** E462–E468. (doi:10.1152/ajpendo.00064.2004)
- Mehta SR, Thomas EL, Patel N, Crofton ME, McCarthy J, Eliahoo J, Morin SX, Fitzpatrick J, Durighel G, Goldstone AP *et al.* Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification. *Hepatology Research* 2010 **40** 399–406. (doi:10.1111/j.1872-034X.2009.00620.x)
- Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L & Falezza G. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. *Diabetic Medicine* 2006 **23** 403–409. (doi:10.1111/j.1464-5491.2006.01817.x)
- Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A & Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterology* 2006 **6** 33. (doi:10.1186/1471-230X-6-33)
- Targher G, Marra F & Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? *Diabetologia* 2008 **51** 1947–1953. (doi:10.1007/s00125-008-1135-4)
- Bedogni G, Kahn HS, Bellentani S & Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. *BMC Gastroenterology* 2010 **10** 98. (doi:10.1186/1471-230X-10-98)
- Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW *et al.* Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. *Digestive and Liver Disease* 2010 **42** 503–508. (doi:10.1016/j.dld.2009.08.002)
- Carvalho JA, Barengo NC, Tuomilehto J, Conceição RD & Santos RD. The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. *Annals of Medicine* 2011 **43** 487–494. (doi:10.3109/07853890.2011.554428)
- Lerchbaum E, Gruber HJ, Schwetz V, Giuliani A, Möller R, Pieber TR & Obermayer-Pietsch B. Fatty liver index in polycystic ovary syndrome. *European Journal of Endocrinology* 2011 **165** 935–943. (doi:10.1530/EJE-11-0614)
- Cicero AF, D'Addato S, Reggi A, Reggiani GM & Borghi C. Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. *Internal and Emergency Medicine* 2013 **8** 265–267. (doi:10.1007/s11739-012-0875-9)
- Wehr E, Gruber HJ, Giuliani A, Möller R, Pieber TR & Obermayer-Pietsch B. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. *Journal of Clinical Endocrinology and Metabolism* 2011 **96** E986–E990. (doi:10.1210/jc.2011-0031)
- Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. *Diabetes Care* 2006 **29** 151–153. (doi:10.2337/diacare.29.01.06.dc05-1805)
- Calori G, Lattuada G, Ragona F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L & Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. *Hepatology* 2011 **54** 145–152. (doi:10.1002/hep.24356)
- Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E & RISC Investigators. Fatty liver index, γ -glutamyltransferase, and early carotid plaques. *Hepatology* 2012 **55** 1406–1415. (doi:10.1002/hep.25555)
- Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B & RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. *Hepatology* 2009 **49** 1537–1544. (doi:10.1002/hep.22845)
- Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH & Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. *Clinical Gastroenterology and Hepatology* 2013 **11** 1201–1204. (doi:10.1016/j.cgh.2012.12.031)
- Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratzin V, Halpern Z, Oren R & Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. *World Journal of Gastroenterology* 2013 **19** 57–64. (doi:10.3748/wjg.v19.i1.57)
- Bozkurt L, Gobl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G & Gastaldelli A. Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. *PLoS ONE* 2012 **7** e32710. (doi:10.1371/journal.pone.0032710)
- Alberti KG, Zimmet P, Shaw J & IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. *Lancet* 2005 **366** 1059–1062. (doi:10.1016/S0140-6736(05)67402-8)

- 23 Pugh CJ, Cuthbertson DJ, Sprung VS, Kemp GJ, Richardson P, Umpleby AM, Green DJ, Cable NT & Jones H. Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. *American Journal of Physiology. Endocrinology and Metabolism* 2013 **305** E50–E58. (doi:10.1152/ajpendo.00055.2013)
- 24 Weickert MO, Roden M, Isken F, Hoffmann D, Nowotny P, Osterhoff M, Blaut M, Alpert C, Gögebakan O, Bumke-Vogt C *et al.* Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans. *American Journal of Clinical Nutrition* 2011 **94** 459–471. (doi:10.3945/ajcn.110.004374)
- 25 Thomas EL, Hamilton G, Patel N, O'Dwyer R, Doré CJ, Goldin RD, Bell JD & Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. *Gut* 2005 **54** 122–127. (doi:10.1136/gut.2003.036566)
- 26 Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ *et al.* Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. *Journal of Clinical Endocrinology and Metabolism* 2012 **97** 3709–3716. (doi:10.1210/jc.2012-1382)
- 27 Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. In *Statistics for Biology and Health*, pp 1–500. Eds M Gail, J Samet, A Tsiatis & W Wong. Springer: New York, USA, 2009. (doi:10.1007/978-0-387-77244-8)
- 28 Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM *et al.* Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes Care* 2011 **34** 1139–1144. (doi:10.2337/dc10-2229)
- 29 Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L *et al.* Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. *Gastroenterology* 2009 **137** 865–872. (doi:10.1053/j.gastro.2009.06.005)
- 30 Balkau B, Lange C, Vol S, Fumeron F, Bonnet F & Group Study DESIR. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. *BMC Gastroenterology* 2010 **10** 56. (doi:10.1186/1471-230X-10-56)

Received 10 February 2014

Revised version received 27 June 2014

Accepted 6 August 2014